A randomized, double-blind, placebo-controlled phase II study to investigate the efficacy and safety of riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in patients with symptomatic pulmonary hypertension associated with idiopathic interstitial pneumonias (IIP).
2020-07-04
عنوان الدراسة
A randomized, double-blind, placebo-controlled phase II study to investigate the efficacy and safety of riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in patients with symptomatic pulmonary hypertension associated with idiopathic interstitial pneumonias (IIP).
داعم الدراسة
Bayer
دواء الدراسة
Riociguat
رقم بروتوكول الدراسة
BAY 63-2521 / 13605
حالة الدراسة
Completed
موقع الدراسة
King Fahad Medical City (Riyadh), King Khalid University Hospital (Riyadh)
مرحلة الدراسة
2
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。